Daily Dose Equities - Wall Street Analysis for Biomedical Research - Daily Dose Newsroom - Rodman & Renshaw on Amylin: Bydureon Posts Flat NRx Market Share, While GLP-1 TRx Grow Over 5% Sequentially (AMLN)

Daily Dose Newsroom Index

Top

Search Daily Dose & Film Annex

BIO SmartBrief

Daily Dose Newsletter

Tuesday

May152012

Rodman & Renshaw on Amylin: Bydureon Posts Flat NRx Market Share, While GLP-1 TRx Grow Over 5% Sequentially (AMLN)

DDE Editor

Amylin Pharmaceuticals, Inc. (NASDAQ:AMLN) is a biopharmaceutical company dedicated to improving lives of patients through the discovery, development and commercialization of innovative medicines. The company is particularly focused on the therapeutic potential of new peptide hormone drug candidates and the creation of novel and groundbreaking therapies for the treatment of diabetes, obesity, and other metabolic diseases.

Rodman & Renshaw has released a report on Amylin, assigning it a Market Underperform/Speculative Risk with a $22 target price.

Analyst Michael G. King writes,

"We maintain our Market Underperform rating and a $22 target. We continue to believe our skepticism is justified given the company’s history of poor execution and the most recent quarter’s fair-to-middling (in our opinion) results. We continue to believe the exenatide franchise is unwanted by those who already have a presence in the diabetes space and a sub-optimal set of assets for those companies to gain a presence in the diabetes/metabolic disease space. In our opinion, AMLN management would have done well to accept the BMY offer of $22 per share; justifying our price target on the shares."

Read the full report below.

Rodman renshaw report on amln 5 14-12

View more documents from DailyDoseEquities

References (20)

References allow you to track sources for this article, as well as articles that were written in response to this article.

Response: More about the author

at More about the author on November 7, 2013

Amazing Web page, Carry on the wonderful job. Thanks a ton.
Response: simply click the next website page

at simply click the next website page on May 8, 2014

Daily Dose Equities - Wall Street Analysis for Biomedical Research - Daily Dose Newsroom - Rodman & Renshaw on Amylin: Bydureon Posts Flat NRx Market Share, While GLP-1 TRx Grow Over 5% Sequentially (AMLN)
Response: ets-inc.com

at ets-inc.com on May 21, 2014

Daily Dose Equities - Wall Street Analysis for Biomedical Research - Daily Dose Newsroom - Rodman & Renshaw on Amylin: Bydureon Posts Flat NRx Market Share, While GLP-1 TRx Grow Over 5% Sequentially (AMLN)
Response: try these out

at try these out on June 29, 2014

Daily Dose Equities - Wall Street Analysis for Biomedical Research - Daily Dose Newsroom - Rodman & Renshaw on Amylin: Bydureon Posts Flat NRx Market Share, While GLP-1 TRx Grow Over 5% Sequentially (AMLN)
Response: mouse click for source

at mouse click for source on July 10, 2014

Daily Dose Equities - Wall Street Analysis for Biomedical Research - Daily Dose Newsroom - Rodman & Renshaw on Amylin: Bydureon Posts Flat NRx Market Share, While GLP-1 TRx Grow Over 5% Sequentially (AMLN)
Response: click through the following web site

at click through the following web site on July 18, 2014

Daily Dose Equities - Wall Street Analysis for Biomedical Research - Daily Dose Newsroom - Rodman & Renshaw on Amylin: Bydureon Posts Flat NRx Market Share, While GLP-1 TRx Grow Over 5% Sequentially (AMLN)
Response: http://meilady.net/steam-cleaning-hardwood-floors/

at http://meilady.net/steam-cleaning-hardwood-floors/ on August 7, 2014

Daily Dose Equities - Wall Street Analysis for Biomedical Research - Daily Dose Newsroom - Rodman & Renshaw on Amylin: Bydureon Posts Flat NRx Market Share, While GLP-1 TRx Grow Over 5% Sequentially (AMLN)
Response: click through the following web site

at click through the following web site on August 19, 2014

Daily Dose Equities - Wall Street Analysis for Biomedical Research - Daily Dose Newsroom - Rodman & Renshaw on Amylin: Bydureon Posts Flat NRx Market Share, While GLP-1 TRx Grow Over 5% Sequentially (AMLN)
Response: http://www.thinking-island.com/

at http://www.thinking-island.com/ on August 26, 2014

Daily Dose Equities - Wall Street Analysis for Biomedical Research - Daily Dose Newsroom - Rodman & Renshaw on Amylin: Bydureon Posts Flat NRx Market Share, While GLP-1 TRx Grow Over 5% Sequentially (AMLN)
Response: http://www.hazoom.com/profile/ne4241.html

at http://www.hazoom.com/profile/ne4241.html on August 27, 2014

Daily Dose Equities - Wall Street Analysis for Biomedical Research - Daily Dose Newsroom - Rodman & Renshaw on Amylin: Bydureon Posts Flat NRx Market Share, While GLP-1 TRx Grow Over 5% Sequentially (AMLN)
Response: kaffeeautomaten berlin

at kaffeeautomaten berlin on August 31, 2014

Daily Dose Equities - Wall Street Analysis for Biomedical Research - Daily Dose Newsroom - Rodman & Renshaw on Amylin: Bydureon Posts Flat NRx Market Share, While GLP-1 TRx Grow Over 5% Sequentially (AMLN)
Response: http://www.lunpanpj.com/

at http://www.lunpanpj.com/ on September 19, 2014

Daily Dose Equities - Wall Street Analysis for Biomedical Research - Daily Dose Newsroom - Rodman & Renshaw on Amylin: Bydureon Posts Flat NRx Market Share, While GLP-1 TRx Grow Over 5% Sequentially (AMLN)
Response: hoahomeloan.com

at hoahomeloan.com on September 24, 2014

Daily Dose Equities - Wall Street Analysis for Biomedical Research - Daily Dose Newsroom - Rodman & Renshaw on Amylin: Bydureon Posts Flat NRx Market Share, While GLP-1 TRx Grow Over 5% Sequentially (AMLN)
Response: Read the Full Article

at Read the Full Article on October 9, 2014

Daily Dose Equities - Wall Street Analysis for Biomedical Research - Daily Dose Newsroom - Rodman & Renshaw on Amylin: Bydureon Posts Flat NRx Market Share, While GLP-1 TRx Grow Over 5% Sequentially (AMLN)
Response: http://deepsoso.com/

at http://deepsoso.com/ on October 15, 2014

Daily Dose Equities - Wall Street Analysis for Biomedical Research - Daily Dose Newsroom - Rodman & Renshaw on Amylin: Bydureon Posts Flat NRx Market Share, While GLP-1 TRx Grow Over 5% Sequentially (AMLN)
Response: Küchenwaage

at Küchenwaage on October 16, 2014

Daily Dose Equities - Wall Street Analysis for Biomedical Research - Daily Dose Newsroom - Rodman & Renshaw on Amylin: Bydureon Posts Flat NRx Market Share, While GLP-1 TRx Grow Over 5% Sequentially (AMLN)
Response: Küchenwaage

at Küchenwaage on October 16, 2014

Daily Dose Equities - Wall Street Analysis for Biomedical Research - Daily Dose Newsroom - Rodman & Renshaw on Amylin: Bydureon Posts Flat NRx Market Share, While GLP-1 TRx Grow Over 5% Sequentially (AMLN)
Response: Thinking-Island.com

at Thinking-Island.com on October 17, 2014

Daily Dose Equities - Wall Street Analysis for Biomedical Research - Daily Dose Newsroom - Rodman & Renshaw on Amylin: Bydureon Posts Flat NRx Market Share, While GLP-1 TRx Grow Over 5% Sequentially (AMLN)
Response: Carson City Restaurants

at Carson City Restaurants on October 26, 2014

Daily Dose Equities - Wall Street Analysis for Biomedical Research - Daily Dose Newsroom - Rodman & Renshaw on Amylin: Bydureon Posts Flat NRx Market Share, While GLP-1 TRx Grow Over 5% Sequentially (AMLN)
Response: Carson City Restaurants

at Carson City Restaurants on October 26, 2014

Daily Dose Equities - Wall Street Analysis for Biomedical Research - Daily Dose Newsroom - Rodman & Renshaw on Amylin: Bydureon Posts Flat NRx Market Share, While GLP-1 TRx Grow Over 5% Sequentially (AMLN)

Reader Comments

There are no comments for this journal entry. To create a new comment, use the form below.

Post a New Comment

Enter your information below to add a new comment.

My response is on my own website »

Author:

Author Email (optional):

Author URL (optional):

Post:

↓ | ↑

Some HTML allowed: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <code> <em> <i> <strike> <strong>

Copyright by Daily Dose Equities. All rights reserved. This website contains information and opinions based on data obtained from reliable sources, which is current as of the publication date, and does not constitute a recommendation that any of the securities mentioned herein are appropriate for any specific individual circumstances and does not guarantee that future results or performance will match those predicted to occur. Although every effort is made to ensure the accuracy and completeness of the information on this website by using reliable data sources such as SEC filings and press releases, no guarantees are made in this regard as it has not been reviewed or certified by an independent auditor and may also include the opinions and future projections of the author. The contributing authors on this website are not chartered financial analysts, registered investment advisors or broker/dealers, and do not provide individual investment advice. The information provided by the writers on this website is for informational purposes only and should not be construed as an offer to buy or sell or a solicitation of an offer to buy or sell any financial instruments or to participate in any particular trading strategy in any jurisdiction. The information appearing on this website, blog, and related publications has not been reviewed or endorsed by any of the companies mentioned and should not be regarded as offical corporate news, publications, or shareholder communications. Film Annex Capital Partners, LLC (FACP) is the owner of this website and they provide strategic advisory, social media, and marketing services to emerging-growth companies. A number of the companies displayed on this site may be current or previous clients of FACP. In most instances, FACP has received fees for services for the creation, preparation and distribution of materials featured on this site, which are paid for in cash and/or stock, by the featured company ("client"). More detailed disclosure regarding fees paid is available upon request. FACP is not a broker/dealer or registered investment advisor. Information contained throughout this site is not an offer to buy or sell securities. Information presented on this site is solely for informative purposes, and is not intended, nor should they be construed, as investment advice. The information provided including news, blogs, corporate profiles, and other material is not intended for distribution to, or use by, any person or entity in any jurisdiction or country where such distribution or use would be contrary to law or regulation or which would subject us to any registration requirement within such jurisdiction or country. The companies featured on this site are typically development-stage and investment in such securities is considered highly speculative and carries a high degree of risk. Complete loss of capital is a distinct possibility. We encourage our readers to invest carefully and read the investor information available at the web sites of the U.S. Securities and Exchange Commission (SEC) at www.sec.gov and the Financial Industry Regulatory Authority (FINRA) at www.finra.org. Opinions stated herein may be solely FACP or the indicated source's, and not necessarily those of the featured Company. Officers, directors, and employees of FACP and financial analysts mentioned, and/or members of their families, may hold a position and may, from time to time, trade in these securities for their own accounts. Specific information in this regard will be furnished upon request. Trademarks are the property of their respective owners. 2010-12 Film Annex Capital Partners, LLC. All rights reserved.